Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Eledon Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PHASE 2 BESTOW TRIAL DATA EVALUATING TEGOPRUBART IN KIDNEY TRANSPLANTATION SHOWED FAVORABLE EFFICACY, SAFETY AND TOLERABILITY, SUPPORTING ADVANCEMENT INTO PHASE 3 DEVELOPMENT REPORTED POSITIVE PRELIMINARY RESULTS FROM FIRST SIX PATIENTS WITH TYPE 1 DIABETES TREATED WITH TEGOPRUBART FOLLOWING ISLET TRANSPLANTATION IN UCHICAGO MEDICINE-LED STUDY TEGOPRUBART CONTINUES TO BE USED AS KEY COMPONENT OF IMMUNOSUPPRESSION REGIMEN IN XENOTRANSPLANTS, INCLUDING THREE TRANSPLANTS OF A GENETICALLY MODIFIED PIG KIDNEY INTO A HUMAN AT MASSACHUSETTS GENERAL HOSPITAL COMPLETED $57.5 MILLION FINANCING, WITH FUNDS EXPECTED TO SUPPORT OPERATIONS INTO 2Q 2027 IRVINE, CALIF., JAN. 08, 2026 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC. (ELEDON) (NASDAQ: ELDN) TODAY ANNOUNCED A SUMMARY OF 2025 ACCOMPLISHMENTS AND PROVIDED GUIDANCE FOR ANTICIPATED UPCOMING 2026 BUSINESS MILESTONES.

ELEDON PHARMACEUTICALS HIGHLIGHTS RECENT BUSINESS MILESTONES AND PROVIDES 2026 OUTLOOK

IRVINE, CALIF., DEC. 01, 2025 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC. (ELEDON) (NASDAQ: ELDN) TODAY ANNOUNCED THAT DAVID-ALEXANDRE C.

ELEDON PHARMACEUTICALS TO PARTICIPATE IN THE 37TH ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE

ELEDON REPORTS DATA FROM FIRST SIX PATIENTS WITH TYPE 1 DIABETES TREATED WITH TEGOPRUBART AS THE CORE IMMUNOSUPPRESSANT FOLLOWING ISLET TRANSPLANTATION

ELEDON REPORTS PRELIMINARY DATA FROM FIRST SIX PATIENTS WITH TYPE 1 DIABETES TREATED WITH TEGOPRUBART AS THE CORE IMMUNOSUPPRESSANT FOLLOWING ISLET TRANSPLANTATION IN INVESTIGATOR-INITIATED TRIAL AT UCHICAGO MEDICINE

DATA FROM PHASE 2 BESTOW TRIAL DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE, SUBSTANTIALLY REDUCING THE METABOLIC, NEUROLOGIC, AND CARDIOVASCULAR TOXICITIES COMMONLY ASSOCIATED WITH TACROLIMUS DATA SUPPORTS ADVANCEMENT INTO PHASE 3 DEVELOPMENT AS A POTENTIAL NEW STANDARD FOR THE PREVENTION OF KIDNEY TRANSPLANT REJECTION STRENGTHENED BALANCE SHEET WITH $57.5 MILLION FINANCING TO ADVANCE TRANSPLANTATION PROGRAMS IRVINE, CALIF., NOV. 14, 2025 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC. (ELEDON) (NASDAQ: ELDN) TODAY REPORTED ITS THIRD QUARTER 2025 OPERATING AND FINANCIAL RESULTS AND REVIEWED RECENT BUSINESS HIGHLIGHTS.

ELEDON PHARMACEUTICALS ANNOUNCES RECENT BUSINESS HIGHLIGHTS AND THIRD QUARTER 2025 FINANCIAL RESULTS

IRVINE, CALIF., NOV. 12, 2025 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC. (ELEDON) (NASDAQ: ELDN), TODAY ANNOUNCED THE PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF (I) 15,152,485 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $1.65 PER SHARE AND (II) IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE UP TO AN AGGREGATE OF 15,151,515 SHARES OF COMMON STOCK AT A PUBLIC OFFERING PRICE OF $1.649 PER PRE-FUNDED WARRANT.

ELEDON PHARMACEUTICALS ANNOUNCES PRICING OF $50 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

IRVINE, CALIF., NOV. 11, 2025 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC. (ELEDON) (NASDAQ: ELDN), TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK.

ELEDON PHARMACEUTICALS ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

DATA FROM PATIENTS WHO REMAINED ON TEGOPRUBART FOR A YEAR POST TRANSPLANT SHOWED AN OVERALL MEAN 12-MONTH ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) OF APPROXIMATELY 69 ML/MIN/1.73 M TEGOPRUBART DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE, SUBSTANTIALLY REDUCING THE METABOLIC, NEUROLOGIC, AND CARDIOVASCULAR TOXICITIES COMMONLY ASSOCIATED WITH TACROLIMUS SUPPORTS ADVANCEMENT INTO PHASE 3 DEVELOPMENT AS A POTENTIAL NEW STANDARD FOR THE PREVENTION OF KIDNEY TRANSPLANT REJECTION CONFERENCE CALL TO BE HELD FRIDAY, NOVEMBER 7 AT 8:00 A.M. ET IRVINE, CALIF.

ELEDON PRESENTS PHASE 2 BESTOW TRIAL RESULTS FOR TEGOPRUBART FOR THE PREVENTION OF REJECTION IN KIDNEY TRANSPLANTATION AT THE AMERICAN SOCIETY OF NEPHROLOGY'S KIDNEY WEEK 2025 ANNUAL MEETING

IRVINE, CALIF., NOV. 05, 2025 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC. (ELEDON) (NASDAQ: ELDN) TODAY ANNOUNCED THAT DAVID-ALEXANDRE C.

ELEDON PHARMACEUTICALS TO PRESENT AT GUGGENHEIM SECOND ANNUAL HEALTHCARE INNOVATION CONFERENCE

ELEDON PHARMACEUTICALS TO PRESENT RESULTS FROM PHASE 2 BESTOW TRIAL OF TEGOPRUBART FOR THE PREVENTION OF REJECTION IN KIDNEY TRANSPLANTATION AT KIDNEY WEEK

ELEDON PHARMACEUTICALS TO PRESENT RESULTS FROM PHASE 2 BESTOW TRIAL OF TEGOPRUBART FOR THE PREVENTION OF REJECTION IN KIDNEY TRANSPLANTATION AT THE AMERICAN SOCIETY OF NEPHROLOGY KIDNEY WEEK 2025 ANNUAL MEETING

IRVINE, CALIF., SEPT. 24, 2025 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC. (ELEDON) (NASDAQ: ELDN) TODAY ANNOUNCED THAT STEVE PERRIN, PH.D.

ELEDON PHARMACEUTICALS TO PRESENT AT THE 18TH CONGRESS OF THE INTERNATIONAL XENOTRANSPLANTATION ASSOCIATION

IRVINE, CALIF., AUG. 29, 2025 (GLOBE NEWSWIRE) -- ELEDON PHARMACEUTICALS, INC. (ELEDON) (NASDAQ: ELDN) TODAY ANNOUNCED THAT DAVID-ALEXANDRE C.

Eledon Pharmaceuticals, Inc.

ELDN

Price

Financial Reports

No items found.

Press Releases

Eledon Pharmaceuticals, Inc.

ELDN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ELDN